Jump to content

5-MeO-MET: Difference between revisions

Add links
From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
m Stub sorting
Line 14: Line 14:
}}
}}


'''5-MeO-MET''' ('''5-Methoxy-N-methyl-N-ethyltryptamine''') is a relatively rare [[designer drug]] from the [[substituted tryptamine]] family, related to compounds such as [[N-Methyl-N-ethyltryptamine]] and [[5-MeO-DMT]].<ref>Schifano F, Orsolini L, Papanti D, Corkery J. NPS: Medical Consequences Associated with Their Intake. ''Curr Top Behav Neurosci''. 2017;32:351-380. {{doi|10.1007/7854_2016_15}} {{pmid|27272067}}</ref><ref>Palma-Conesa AJ, Ventura M, Galindo L, Fonseca F, Grifell M, Quintana P, Fornís I, Gil C, Farré M, Torrens M. Something New about Something Old: A 10-Year Follow-Up on Classical and New Psychoactive Tryptamines and Results of Analysis. ''Journal of Psychoactive Drugs'' 2017; 49(4): 297-305. {{doi|10.1080/02791072.2017.1320732}}</ref><ref>Malaca S, Lo Faro AF, Tamborra A, Pichini S, Busardò FP, Huestis MA. Toxicology and Analysis of Psychoactive Tryptamines. ''International Journal of Molecular Sciences''. 2020; 21(23):9279. {{doi|10.3390/ijms21239279}}</ref> It was first synthesised in the 1960s and was studied to a limited extent,<ref>Gessner PK, Godse DD, Krull AH, McMullan JM. Structure-activity relationships among 5-methoxy-N:N-dimethyltryptamine, 4-hydroxy-N:N-dimethyltryptamine (psilocin) and other substituted tryptamines. ''Life Sci''., 1 Mar 1968, 7(5): 267–277. {{doi|10.1016/0024-3205(68)90200-2}}</ref><ref>Glennon RA, Gessner PK. Serotonin receptor binding affinities of tryptamine analogues. ''J. Med. Chem''., 1 Jan 1979, 22 (4), pp 428–432. {{doi|10.1021/jm00190a014}}</ref> but was first identified on the illicit market in June 2012 in Sweden.<ref>[https://www.emcdda.europa.eu/system/files/publications/734/EMCDDA-Europol_2012_Annual_Report_final_439477.pdf EMCDDA–Europol 2012 Annual Report on the implementation of Council Decision 2005/387/JHA (New drugs in Europe, 2012]</ref> It was made illegal in Norway in 2013,<ref>[https://lovdata.no/dokument/LTI/forskrift/2013-12-16-1557 Forskrift om endring i forskrift om narkotika]</ref> and is controlled under analogue provisions in numerous other jurisdictions.
'''5-MeO-MET''' ('''5-Methoxy-N-methyl-N-ethyltryptamine''') is a relatively rare [[designer drug]] from the [[substituted tryptamine]] family, related to compounds such as [[N-methyl-N-ethyltryptamine]] and [[5-MeO-DMT]].<ref>Schifano F, Orsolini L, Papanti D, Corkery J. NPS: Medical Consequences Associated with Their Intake. ''Curr Top Behav Neurosci''. 2017;32:351-380. {{doi|10.1007/7854_2016_15}} {{pmid|27272067}}</ref><ref>Palma-Conesa AJ, Ventura M, Galindo L, Fonseca F, Grifell M, Quintana P, Fornís I, Gil C, Farré M, Torrens M. Something New about Something Old: A 10-Year Follow-Up on Classical and New Psychoactive Tryptamines and Results of Analysis. ''Journal of Psychoactive Drugs'' 2017; 49(4): 297-305. {{doi|10.1080/02791072.2017.1320732}}</ref><ref>Malaca S, Lo Faro AF, Tamborra A, Pichini S, Busardò FP, Huestis MA. Toxicology and Analysis of Psychoactive Tryptamines. ''International Journal of Molecular Sciences''. 2020; 21(23):9279. {{doi|10.3390/ijms21239279}}</ref> It was first synthesised in the 1960s and was studied to a limited extent,<ref>Gessner PK, Godse DD, Krull AH, McMullan JM. Structure-activity relationships among 5-methoxy-N:N-dimethyltryptamine, 4-hydroxy-N:N-dimethyltryptamine (psilocin) and other substituted tryptamines. ''Life Sci''., 1 Mar 1968, 7(5): 267–277. {{doi|10.1016/0024-3205(68)90200-2}}</ref><ref>Glennon RA, Gessner PK. Serotonin receptor binding affinities of tryptamine analogues. ''J. Med. Chem''., 1 Jan 1979, 22 (4), pp 428–432. {{doi|10.1021/jm00190a014}}</ref> but was first identified on the illicit market in June 2012 in Sweden.<ref>[https://www.emcdda.europa.eu/system/files/publications/734/EMCDDA-Europol_2012_Annual_Report_final_439477.pdf EMCDDA–Europol 2012 Annual Report on the implementation of Council Decision 2005/387/JHA (New drugs in Europe, 2012]</ref> It was made illegal in Norway in 2013,<ref>[https://lovdata.no/dokument/LTI/forskrift/2013-12-16-1557 Forskrift om endring i forskrift om narkotika]</ref> and is controlled under analogue provisions in numerous other jurisdictions.


== See also ==
== See also ==
Line 33: Line 33:




{{Pharm-stub}}
{{nervous-system-drug-stub}}

Revision as of 12:36, 29 August 2021

5-MeO-MET
Identifiers
  • N-Ethyl-2-(5-methoxy-1H-indol-3-yl)-N-methylethan-1-amine
CAS Number
PubChem CID
ChemSpider
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC14H20N2O
Molar mass232.327 g·mol−1
3D model (JSmol)
  • CCN(CCc1c[nH]c2c1cc(OC)cc2)C
  • InChI=1S/C14H20N2O/c1-4-16(2)8-7-11-10-15-14-6-5-12(17-3)9-13(11)14/h5-6,9-10,15H,4,7-8H2,1-3H3
  • Key:AVECDEWGCOLCPZ-UHFFFAOYSA-N

5-MeO-MET (5-Methoxy-N-methyl-N-ethyltryptamine) is a relatively rare designer drug from the substituted tryptamine family, related to compounds such as N-methyl-N-ethyltryptamine and 5-MeO-DMT.[1][2][3] It was first synthesised in the 1960s and was studied to a limited extent,[4][5] but was first identified on the illicit market in June 2012 in Sweden.[6] It was made illegal in Norway in 2013,[7] and is controlled under analogue provisions in numerous other jurisdictions.

See also

References

  1. ^ Schifano F, Orsolini L, Papanti D, Corkery J. NPS: Medical Consequences Associated with Their Intake. Curr Top Behav Neurosci. 2017;32:351-380. doi:10.1007/7854_2016_15 PMID 27272067
  2. ^ Palma-Conesa AJ, Ventura M, Galindo L, Fonseca F, Grifell M, Quintana P, Fornís I, Gil C, Farré M, Torrens M. Something New about Something Old: A 10-Year Follow-Up on Classical and New Psychoactive Tryptamines and Results of Analysis. Journal of Psychoactive Drugs 2017; 49(4): 297-305. doi:10.1080/02791072.2017.1320732
  3. ^ Malaca S, Lo Faro AF, Tamborra A, Pichini S, Busardò FP, Huestis MA. Toxicology and Analysis of Psychoactive Tryptamines. International Journal of Molecular Sciences. 2020; 21(23):9279. doi:10.3390/ijms21239279
  4. ^ Gessner PK, Godse DD, Krull AH, McMullan JM. Structure-activity relationships among 5-methoxy-N:N-dimethyltryptamine, 4-hydroxy-N:N-dimethyltryptamine (psilocin) and other substituted tryptamines. Life Sci., 1 Mar 1968, 7(5): 267–277. doi:10.1016/0024-3205(68)90200-2
  5. ^ Glennon RA, Gessner PK. Serotonin receptor binding affinities of tryptamine analogues. J. Med. Chem., 1 Jan 1979, 22 (4), pp 428–432. doi:10.1021/jm00190a014
  6. ^ EMCDDA–Europol 2012 Annual Report on the implementation of Council Decision 2005/387/JHA (New drugs in Europe, 2012
  7. ^ Forskrift om endring i forskrift om narkotika


Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=5-MeO-MET&oldid=1041244010"